SET AND READY TO UNLEASH THE POTENTIAL OF THE PHARMACIST HEALTH WORKFORCE Government aligns Scope of Practice review with Pharmacists in 2030 report
Filmed in Perth, Western Australia, November 2024
With Associate Professor Fei Sim, National President
Pharmaceutical Society of Australia (PSA)
Last week, Associate Professor Fei Sim the National President of the Pharmaceutical Society of Australia (PSA), the peak body representing 39,000 pharmacists across Australia’s health system, spoke to Australian Health Journal about the release of the Unleashing the Potential of our Health Workforce – Scope of Practice Review. The review and final report sets out to create a clear pathway for health professionals to contribute more to our health system and practice to their full and top of scope.
The report calls for governments to remove the inconsistent barriers that restrict the scope of healthcare professionals, including pharmacists.
PSA National President Associate Professor Fei Sim FPS commended the report’s focus on removing barriers for pharmacists and other healthcare professionals as a critical step towards a more accessible and resilient healthcare system.
“This review confirms PSA’s view that inconsistent regulations, unnecessary restrictions on practice, and siloed workforces are having a negative impact on patient access to quality health care,” Associate Professor Sim said.
“Pharmacists are some of the most accessible healthcare professionals in our communities, yet regulatory barriers continue to limit our ability to provide care when and where our patients need it. The release of this final report is the next step towards breaking down these barriers through a short- and long-term reform agenda, addressing the inefficiencies in our health system.”
Associate Professor Sim said that the report’s recommendations present a genuine opportunity to improve access to health care across Australia.
“There is a clear alignment between Cormack’s recommendations and the actions in PSA’s vision for the pharmacy profession, Pharmacists in 2030. Both present a clear vision for the future that requires collaboration for a health system that works for patients,” Associate Professor Sim said.
“This report recognises the core role of pharmacies and pharmacists as primary healthcare providers and recommends a multidisciplinary approach to patient care.
“In order to make the most of the opportunities presented by the report, we need governments, regulators and health care professionals to work together for a strong, sustainable health system that utilises all health professionals to their full scope.
“I urge governments and stakeholders at all levels to accept and act on the report’s recommendations in full to build a health system ready for the growing health needs of Australians.”
A/Prof Fei Sim served on the Cormack Review’s Expert Advisory Committee, representing the pharmacy profession.
-
New Generative AI and machine learning frontier on unused patient care data
Drawing from GE’s 125-year legacy in healthcare, Amit Yadav, CEO GE HealthCare ANZ is leading efforts to integrate AI into medical imaging devices and optimise workflow efficiencies. He stresses the importance of leveraging the vast amount of untapped healthcare data, with an emphasis on automating manual processes to enhance productivity. Additionally, his focus extends to utilising AI for workflow optimisation and ensuring compliance with local regulations and standards to prioritise safety.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
